• Call: 301-363-4651
  • Email: [email protected]
Cusabio Life Science – Your Biology Science Partner
All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
  • Peptide
  • Home
  • Products
    Kits
    • ELISA Kits
    • Exosome Isolation Kits
    • ELISA Kits For Food Safety & Drug Residues
    • Plasmid DNA Purification Maxiprep Kit
    • HCP Detection ELISA Kit
    Proteins
    • Active Proteins*
    • Native Proteins
    • Recombinant Proteins
    • Transmembrane Proteins
    Antibodies
    • Recombinant Antibodies
    • Monoclonal Antibodies
    • Polyclonal Antibodies
    • Secondary Antibodies
    • Tag/Control Antibodies
    • Small Molecular Antibodies
    • ChIP Antibodies
    • Antibody Pairs
    • Custom Antibodies
    • Modified Histone Antibodies
    • Biosimilar Antibodies
    Biochemical Reagents
    • Cell Electrofusion Buffer
    Stable Cell Line Clone Peptide
    • Cosmetic Peptide
    • Amino Acids and Derivatives
    Small Molecule
    • Food Safety Small Molecular Antigens
    • Other Small Molecular Antigens

    Solutions
    • mRNA Vaccine Research Solutions
    • ADC Development Solutions
    • CAR-T Therapy Development Solutions
    Hot Categories
    • IS Series Cytokine Detection ELISA Kit*
    • Mini Sample ELISA kit*
    • Notch Receptors and Ligands
    • Claudin (CLDN) Family Proteins
    • Rare Species Antibodies
    • Anti-CAR Linker Antibody
    • Anti-payload Antibodies
    • Immunohistochemistry (IHC) Antibodies
    • Flow Cytometry Antibodies
    • Recombinant DT3C protein
    • Chemokine Receptors
    • G protein-Coupled Receptor
    • Recombinant Antibodies for Drug Discovery
    • Recombinant Proteins for ADCs
    • New Products Launch
  • CRO Service
    Quote for CRO Service Specialized CRO Services
    • Stable Cell Line Developmentm Service
    • Custom Peptide Synthesis
    • SPR Detection Service
    Protein Expression Services
    • Transmembrane Protein Expression Service*
    • E.coli Expression System
    • Yeast Expression System
    • In vitro E.coli Expression System
    • Insect Baculovirus Expression System
    • Mammalian Cell Expression System
    Oligo Synthesis Service Gene Synthesis Service
    Therapeutic Antibody Discovery Service*
    • Mouse hybridoma screening & sequencing
    • Single B Cell Antibody Discovery*
    • VHH library screening
    Custom Antibody Services
    • HTP Recombinant Antibody Production
    • Recombinant Ab Production
    • Monoclonal Ab Production
    • Polyclonal Ab Production
    • Modified Ab Production
    • Anti-idiotype Antibody Production*
      • Home
      • Active Protein
      • Other
      • Recombinant Human Coagulation factor XI (F11) (Active)

      Recombinant Human Coagulation factor XI (F11) (Active)

      In Stock
      Code CSB-MP007916HU(A4)
      Abbreviation Recombinant Human F11 protein (Active)
      MSDS
      MSDS Datasheet
      Size $256
      Order now
      Image
      • (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
      • Activity
        Measured by its binding ability in a functional ELISA. Immobilized Human F11 at 2 μg/ml can bind Anti-F11 recombinant antibody (CSB-RA007916MA1HU). The EC50 is 0.2442-0.2820 ng/mL. Biological Activity Assay
      • Activity
        Measured by its ability to cleave the fluorogenic peptide substrate, t-butyloxycarbonyl-Ile-Glu-Gly-Arg-7-amido-4-methylcoumarin (Boc-IEGR-AMC). The specific activity is >300 pmol/min/µg. Biological Activity Assay
      Have Questions? Leave a Message or Start an on-line Chat
      • Product Details
      • Related Products
      • Customer Reviews and Q&A
      • Target Background

      Product Details

      Purity
      Greater than 95% as determined by SDS-PAGE.
      Endotoxin
      Less than 1.0 EU/ug as determined by LAL method.
      Activity
      ①Measured by its binding ability in a functional ELISA. Immobilized Human F11 at 2 μg/mL can bind Anti-F11 recombinant antibody (CSB-RA007916MA1HU). The EC50 is 0.2442-0.2820 ng/mL.
      ②Measured by its ability to cleave the fluorogenic peptide substrate, t-butyloxycarbonyl-Ile-Glu-Gly-Arg-7-amido-4-methylcoumarin (Boc-IEGR-AMC). The specific activity is >300 pmol/min/µg.
      Target Names
      F11
      Uniprot No.
      P03951
      Alternative Names
      Coagulation factor XI; EC:3.4.21.27; FXI; Plasma thromboplastin antecedent (PTA); F11
      Species
      Homo sapiens (Human)
      Source
      Mammalian cell
      Expression Region
      19-625aa
      Target Protein Sequence
      ECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV
      Mol. Weight
      69.4 kDa
      Protein Length
      Full Length of Mature Protein
      Tag Info
      C-terminal 10xHis-tagged
      Form
      Lyophilized powder
      Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
      Buffer
      Lyophilized from a 0.2 μm sterile filtered PBS, 6% Trehalose, pH 7.4
      Reconstitution
      We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
      Troubleshooting and FAQs
      Protein FAQs
      Storage Condition
      Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
      Shelf Life
      The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
      Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
      Lead Time
      3-7 business days
      Notes
      Repeated freezing and thawing is not recommended. Store working aliquots at 4℃ for up to one week.
      Datasheet & COA
      Please contact us to get it.

      Related Products

      F11 Antibodies

      • F11 Recombinant Monoclonal Antibody ( ELISA ) ( CSB-RA007916MA1HU )
      • F11 Antibody ( ELISA, IHC ) ( CSB-PA007916LA01HU )
      • F11 Antibody, HRP conjugated ( ELISA ) ( CSB-PA007916LB01HU )
      • F11 Antibody, FITC conjugated ( ) ( CSB-PA007916LC01HU )
      • F11 Antibody, Biotin conjugated ( ELISA ) ( CSB-PA007916LD01HU )
      • More>>

      F11 Proteins

      • Recombinant Human Coagulation factor XI (F11), partial ( E.coli-CSB-EP007916HU )
      • Recombinant Human Coagulation factor XI (F11) ( Yeast-CSB-YP007916HU Baculovirus-CSB-BP007916HU Mammalian cell-CSB-MP007916HU In Vivo Biotinylation in E.coli-CSB-EP007916HU-B )

      F11 ELISA kits

      • Human Coagulation factor XI(F11) ELISA kit ( CSB-EL007916HU )

      Customer Reviews and Q&A

      ■ Customer Reviews

      There are currently no reviews for this product.

      Submit a Review here

      Target Background

      Function
      Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX.
      Gene References into Functions
      1. Direct DNA sequencing analysis of the F11 genes revealed that all of the 14 patients had a F11 gene mutation. Eight different mutations were identified in the apple 1, apple 2 or serine protease domains, except one which was a splice site mutation. Six of the mutations were recurrent. PMID: 27723456
      2. The aim of the current study was to analyze, for the first time in the Portuguese population, five well known and replicated venous thromboembolism - associated single nucleotide polymorphisms in genes ABO (rs2519093 and rs8176719), F11 (rs2036914 and rs2289252) and FGG (rs2066865), and to determine its possible association with risk for venous thromboembolism. PMID: 29995659
      3. Data indicate four new factor XI (FXI) gene defects potentially causing a functional deficiency and the duplication of 1653 bp involving exons 8 and 9. PMID: 28960694
      4. In this prospective cohort of elderly adults, there was no statistically significant association of higher FXI levels with incident coronary heart disease and stroke. PMID: 28009647
      5. High molecular weight kininogen has an inhibitory effect on nucleic acid-supported fXI activation and may function as a negative regulator of fXI activation. PMID: 28124063
      6. FXI has a role in promoting a vascular coagulation-inflammatory circuit in arterial hypertension PMID: 28148841
      7. thrombin activatable fibrinolysis inhibitor pathway impairment, largely caused by a hitherto unknown TAFIa resistance, appears to be one main cause of decreased fibrinolytic resistance in FXI deficiency PMID: 27094709
      8. factor XI has a role in procoagulant microparticle-promoted coagulation in human endotoxemia PMID: 26857798
      9. Three loci showed robust, replicating association with circulating FXI levels: KNG1 (rs710446, P-value = 2.07 x 10-302), F11 (rs4253417, P-value = 2.86 x 10-193), and a novel association in GCKR (rs780094, P-value = 3.56 x10-09), here for the first time implicated in FXI regulation. The two first SNPs (rs710446 and rs4253417) also associated with partial thromboplastin time PMID: 28053049
      10. The rs710446 and five low-frequency variant sets in KNG1 with FXI level variation of Factor XI were significant after multiple testing correction and permutation. PMID: 28445521
      11. Exploring the global landscape of genetic variation in coagulation factor XI deficiency PMID: 28615222
      12. Structures of FXI in complex with the laminin-derived peptide EFPDFP and a DFP peptide from the random screen demonstrated binding in the same pocket, although in a slightly different conformation, thus revealing some flexibility in the molecular interactions of the FXI apple 2 domain. PMID: 27006387
      13. inhibition of FXI and FXII distinctly alter the biophysical properties of fibrin. PMID: 27933406
      14. Data show that among the studied polymorphisms, only coagulation factor XI (F11) single nucleotide polymorphism rs2289252 was significantly associated with venous thrombosis (VT) and the F11 rs2289252-A allele was associated with a 1.6-fold increased risk of VT PMID: 27414984
      15. Thus in conclusion, the bleeding manifestations in FXI deficiency are varied and unpredictable; neither correlates with FXI levels nor with the mutations. Comprehensive analysis of all the factors including both plasma and platelet FXI, global hemostatic factors like thrombin generation potential may indicate a potential laboratory indicator for FXI deficiency related bleeding manifestations. PMID: 27710856
      16. Fasudil reduced LPS-mediated TF and PAI-1 expression and activity in PBMCs. These effects may partially be relevant to the clinical benefits of fasudil in the treatment of CAPD patients. PMID: 27756191
      17. rs2289252 and rs2036914 polymorphisms have important role in development of venous thromboembolism in the white race PMID: 28353616
      18. High activity of factor XI indicates a risk of occurrence of deep vein thrombosis in post-trauma patients with fractures. F11 rs2089252 and rs2036914 (single nucleotide polymorphisms) are associated with activity of factors XI in such patients despite prophylaxis. PMID: 27627722
      19. this study confirms the significant associations between polymorphism of 25264C.T in FXI and its activity and the risk of deep vein thrombosis after artificial joint replacement surgery PMID: 26934731
      20. F11 genetic variants are associated with the risk of incident venous thrombosis among women PMID: 26631918
      21. This study characterized FXI deficiency mutation spectrum in Chinese population with a high frequency of the W228*, G400V, Q263* and c.1136-4delGTTG mutations, which is distinct from that of other populations including Korean, Jewish or European populations. PMID: 27067486
      22. factor XI is localized to GPIb in membrane rafts and that this association is important for promoting the activation of factor XI by thrombin on the platelet surface PMID: 12517745
      23. higher basal factor XI concentration in the general population is not a risk marker for stroke or coronary heart disease PMID: 26386215
      24. Factor XI and factor XII activities were significantly higher in patients with slow coronary flow than in controls, and could be associated with enhanced procoagulant state present in these patients. PMID: 24509324
      25. FXI-thrombin axis contributes to distal platelet activation and procoagulant microaggregate formation in the blood flow downstream of the site of thrombus formation. PMID: 26769048
      26. F11 gene variant rs2289252 contributes to inherited forms of deep vein thrombosis incidence in Latvian population. PMID: 25091233
      27. These studies enhance understanding on the first allosteric inhibitor of FXIa and highlight its value as a promising anticoagulant. PMID: 25935648
      28. ROTEM assays failed to distinguish bleeding from non-bleeding patients but could do so between different FXI activity levels and genotypes. PMID: 26160656
      29. increased activity of FXI may be a potential risk factor for miscarriage; high activity of FXI diagnosed in women with history of miscarriage is not probably caused by the presence of SNPs rs2289252 and rs2036914 PMID: 25517908
      30. Data indicate that the mean factor XI (FXI) was not significantly different in laboratories using the same method on both exercises, suggesting good intralaboratory precision over time. PMID: 25976967
      31. Identification of a novel c.290G>A mutation in the F11 gene that is associated with mild Factor XI deficiency in a Dutch Caucasian family. PMID: 25618263
      32. In whites, the FXI variant was associated with both factor XI concentration and venous thromboembolism (VTE) incidence (1.15-fold greater incidence of VTE per risk allele), whereas In African-Americans, these associations were absent. PMID: 26260105
      33. Mass spectrometry analyses of FXI revealed full occupation of two of the three heavy-chain glycosites and almost full-site occupancy of the light chain. Analysis of FXI glycopeptides by LC-MS/MS enabled site-specific glycan profiling and occupancy. PMID: 25092234
      34. This study presents the first application of a new thrombin generation based factor XIa assay. PMID: 25288467
      35. study determined the molecular basis of FXI deficiency in 6 unrelated severely deficient patients in China; reported 8 mutations in FXI gene leading to FXI deficiency; functional consequences of a novel mutation leading to FXI deficiency have been elucidated PMID: 25681615
      36. FXI expression is directly regulated by a specific miRNA, miR-181a-5p, in the human liver PMID: 25379760
      37. FXI may have a role in risk of ischemic stroke, but not myocardial infarct; FXII and prekallikrein may not have a role in either PMID: 24977287
      38. We suggested that the minor allele of rs3756008 in the promoter of FXI gene could reduce its expression in kidney. PMID: 24420855
      39. at variance with other populations, no single major founder effect is present in Italian patients with FXI deficiency. PMID: 24112640
      40. Genetic variants of coagulation factor XI show association with ischemic stroke up to 70 years of age. PMID: 24086496
      41. Identification of a novel candidate F11 gene mutation associated with a cross-reacting material positive plasma FXI deficiency. PMID: 23571684
      42. Studies indicate that in the past two decades, more than 220 mutations in the factor XI (FXI) gene have been reported in patients with FXI deficiency, of which 7 showed a founder effect. PMID: 23929304
      43. a novel mutations in family with inherited factor XI deficiency PMID: 23494098
      44. Propose that long polyphosphates promote FXII-mediated blood coagulation bypassing FXI. PMID: 23659638
      45. The rather rare type I mutation in the FXI gene is a third founder mutation in Ashkenazi Jews with factor XI deficiency. PMID: 23332144
      46. For activation by thrombin, or during autoactivation, the data support a cis-activation mechanism in which the activating protease binds to and activates the same fXI subunit. PMID: 23515926
      47. F11 gene mutational screening revealed 11 different DNA variations, 3 of which had not yet been described PMID: 23305485
      48. Factor XI is a substrate for oxidoreductases: enhanced activation of reduced FXI is found in antiphospholipid syndrome thrombosis. PMID: 22704541
      49. A novel amino acid substitution in the serine protease catalytic domain (Ile463Ser) appears to be responsible for the congenital factor XI deficiency in a Swiss family. PMID: 22322133
      50. The F11 rs2289252 polymorphism is associated with FXI activity levels and APTT ratio in women with thrombosis. PMID: 22633531

      Show More

      Hide All

      Involvement in disease
      Factor XI deficiency (FA11D)
      Subcellular Location
      Secreted.
      Protein Families
      Peptidase S1 family, Plasma kallikrein subfamily
      Tissue Specificity
      Isoform 2 is produced by platelets and megakaryocytes but absent from other blood cells.
      Database Links

      HGNC: 3529

      OMIM: 264900

      KEGG: hsa:2160

      STRING: 9606.ENSP00000384957

      UniGene: Hs.1430

      Promotions
      Reward For Reviews
      Free antibody trial
      Contact Us

        Email: [email protected]
        Distributors Worldwide

      Service

      Phage Display Service

      Antibody Service

      • −  Polyclonal Antibody Production
      • −  Monoclonal Antibody Production
      • −  Custom Recombinant Antibody Production
      • −  Modification-specific Antibody Production

      Protein Service

      • −  E.coli Expression Service
      • −  Yeast Expression Service
      • −  In vitro E.coli Expression System
      • −  Insect baculovirus expression system
      • −  Mammalian Cell Expression System

      Gene Synthesis Service

      Oligo Synthesis Service

      Related Articles
      Osteoprotegerin (OPG): What is Its Potential as a Biomarker or Therapeutic Target? An Overview of Cell Death: Necrosis and Apoptosis The Overview of One Category of Important Cell Receptors: Receptor Tyrosine Kinases CCR8: a Specific Marker on Tregs Cells, the Next Promising Candidate for Antitumor Drugs! Cellular Senescence and Its Markers Interleukin 4 receptor (IL-4R/IL-4Ra): a Multifunctional Target of Cytokines, Suggesting Diverse Potential in Asthma, Rhinitis, Viral, and Tumor Research! Tumor Necrosis Factor Receptor Superfamily and Apoptosis The Overview of Coagulation Monoclonal Antibody Drugs Overview What Are the Effects of Abnormalities in the ALK Gene CD70 (CD27L/TNFSF7): a TNF Receptor Member, a “Star” Target for Clinical Research in Systemic Lupus Erythematosus (SLE), Arthritis, and Tumors! Does TNF Superfamily Inhibit Cancer or Promote Its Development? The Overview of Growth Factor Tumor Necrosis Factor (TNF) The overview of TGF-β signaling pathway Do You Really Know TGF-β Superfamily? Bispecific Antibody Overview: From Definition to Application Oncostatin M (OSM): A Member of IL-6 Cytokine Family, An Underestimated Player in Future Targeted Therapies? CT83/KK-LC-1: a Promising Therapeutic Target of CTAs Family, Currently in Clinical Research for Breast, Lung, Gastric Cancers, and Beyond! MSTN: A Key Target for Targeted Therapy in Muscle Diseases​ CUSABIO's Five Expression Systems General Information of Different Tags How to express a protein with bioactivity? How to choose a suitable expression vector? Applications of recombinant proteins Production of Recombinant Protein
      Related pathways
      Complement and coagulation cascades Target Therapy
      CUSABIO guaranteed quality
    icon of phone
    Call us
    301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
    icon of email
    Email
    [email protected]
    icon of address
    Address
    7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
    icon of social media
    Join us with

    Subscribe newsletter

    Leave a message

    * To protect against spam, please pass the CAPTCHA test below.
    CAPTCHA verification
    © 2007-2026 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
    Privacy Policy
    Message
    • *
    • *
    • Since emails may get flagged by spam filters occasionally, we recommend leaving your phone number as a precaution. Your information is safe with us.

    • *
    • *
    • CAPTCHA verification

      Please enter the characters shown. Click the image to refresh if unclear.

    •  

    ×CloseMessage

    • *
    • *
    • *
    •  
    Place an order now

    I. Product details

    *
    *
    *
    *

    II. Contact details

    *
    *

    III. Ship To

    *
    *
    *
    *
    *
    *
    *

    IV. Bill To

    *
    *
    *
    *
    *
    *
    *
    *